FDA expands ipilimumab approval to pediatric melanoma

Article

The US Food and Drug Administration (FDA) has expanded the approval of ipilimumab (Yervoy) to include the treatment of pediatric melanoma patients 12 years and older with unresectable or metastatic disease.

The US Food and Drug Administration (FDA) has expanded the approval of ipilimumab (Yervoy) to include the treatment of pediatric melanoma patients 12 years and older with unresectable or metastatic disease, CancerNetwork reports. The FDA-approved ipilimumab dose for pediatric melanoma patients is 3 mg/kg, administered intravenously every 3 weeks for four doses.

Read the full report and study details.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.